Prognostic difference between entecavir and tenofovir treatments in patients with hepatitis B related intrahepatic cholangiocarcinoma

Abstract

Abstract: Objective To determine whether the long-term use of different antiviral agents entecavir (ETV) or tenofovir (TDF) has impact on the prognosis of hepatitis B related intrahepatic cholangiocarcinoma (ICC). Methods A retrospective analysis was performed in 96 patients with hepatitis B related ICC, including 25 cases with TDF treatment, and 71 cases with ETV treatment. The long-term overall survival (OS) and disease progression free survival (PFS) periods were compared between the two groups. Results The median OS of TDF group was 38 months and that of ETV was 30 months. The 1-year, 3-year and 5-year survival rates of TDF group were 92.0%, 46.2% and 30.8%, respectively. The 1-year, 3-year and 5-year survival rates of ETV group were 94.1%, 39.9% and 13.5%, respectively, but there was no significant difference between the two groups (P=0.514). The median PFS in TDF group was 25 months, and the 1-year, 3-year and 5-year progression free survival rates were 75.8%, 38.0% and 12.7%, respectively; The median PFS in ETV group was 20 months, and the 1-year, 3-year and 5-year progression free survival rates were 71.1%, 30.0% and 12.9%, respectively. Similarly, there was no significant difference in PFS between the two groups (P=0.403). Cox multivariate analysis showed that TNM stage, radical surgery, lymph node metastasis and HBV DNA > 104 IU/ml were independent prognostic factors. Conclusion There is no significant difference between the treatments with antiviral drugs ETV and TDF in the prognosis of hepatitis B related ICC. This result is awaiting further confirmation by retrospective analysis with a larger number of patients.

Key words: Intrahepatic cholangiocarcinoma, Hepatitis B, Antiviral, Entecavir, Tenofovir

MIAO Hui, SHI Liang-hui, WAN Qian-qian, YANG Zi-yu, SUN Bao-mu, WAN Xu-ying. Prognostic difference between entecavir and tenofovir treatments in patients with hepatitis B related intrahepatic cholangiocarcinoma[J]. Chinese Hepatolgy, 2024, 29(10): 1180-1183.

References

[1] Zhang H, Yang T, Wu M, et al.Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management[J]. Cancer Lett,2016, 379(2):198-205.
[2] Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us[J]? J Hepatol, 2012, 56(4):848-854.
[3] Ke Q ,Lin N,Deng M, et al. The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(2):e0229292.
[4] Clements O,Eliahoo J,Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis[J]. J Hepatol, 2020, 72(1):95-103.
[5] Palmer WC,Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2012, 57(1):69-76.
[6] Corrao S,Natoli G,Argano C. Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis[J]. Eur J Gastroenterol Hepatol, 2021, 33(1):62-68.
[7] Wongjarupong N,Assavapongpaiboon B,Susantitaphong P, et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis[J]. BMC gastroenterol, 2017, 17(1):149.
[8] Lee TY,Hsu YC,Yu SH, et al. Effect of nucleos(t)ide analogue therapy on risk of intrahepatic cholangiocarcinoma in patients with chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2018, 16(6):947-954.e944.
[9] Lei Z,Xia Y,Si A,et al. Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection[J]. J Hepatol, 2018, 68(4):655-662.
[10] Zhang Z,Zhou Y,Yang J, et al.The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis[J]. BMC cancer, 2019, 19(1):511.
[11] Choi J,Kim HJ,Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a korean nationwide cohort study[J]. JAMA oncol, 2019, 5(1):30-36.
[12] Choi J,Jo C,Lim Y S. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection[J]. Hepatology, 2021,73(2): 661-673.
[13] Dave S, Park S, Murad MH, et al. Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis[J]. Hepatology, 2021.73(1): 68-78
[14] Murata K,Asano M,Matsumoto A, et al. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection[J]. Gut, 2018, 67(2):362-371.
[15] Murata K,Tsukuda S,Suizu F, et al. Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection[J]. Hepatology, 2020, 71(5):1533-1545.
[16] Hu JY, Zhou HB, Liu WD, et al. A comparative study of intrahepatic cholangiocarcinoma and hepatocellular carcinoma with reference to clinical features and prognosis[J]. Zhonghua Gan Zang Bing Za Zhi, 2019, 27(7):511-515.